Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data
暂无分享,去创建一个
H. Nishiyama | H. Miyake | C. Ohyama | N. Nishiyama | T. Kojima | H. Kitamura | M. Miyake | K. Fujimoto | F. Hongo | Takashi Kobayashi | Y. Matsui | K. Hashine | Y. Sawada | R. Taoka | S. Hori | Kota Iida | S. Fukui | R. Tomida | R. Minato | M. Matsumura
[1] H. Nishiyama,et al. Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study , 2021, BMC cancer.
[2] C. Dinney,et al. Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate , 2021, Bladder cancer.
[3] G. Steinberg,et al. Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-Invasive Bladder Cancer in US Clinical Practice. , 2020, Urology.
[4] T. Tsuzuki,et al. Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision , 2020, International journal of urology : official journal of the Japanese Urological Association.
[5] A. Kibel,et al. Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. , 2020, Clinical genitourinary cancer.
[6] Shahrokh F. Shariat,et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.
[7] Matthew P. Goetz,et al. NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .
[8] Siteng Chen,et al. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. , 2018, International journal of surgery.
[9] S. Selph,et al. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis , 2017, The Journal of urology.
[10] L. Kiemeney,et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. , 2015, European urology.
[11] R. Sylvester,et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. , 2012, European urology.
[12] T. D. de Reijke,et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010, European urology.
[13] L. Martínez-Piñeiro,et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.
[14] Anirban P. Mitra,et al. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. , 2008, Reviews in urology.
[15] L. Klotz,et al. Urothelial carcinoma of the prostate. , 2007, Urology.
[16] J Alfred Witjes,et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.
[17] P. Sogani,et al. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.